- Home
- SYNX vs IMRN Comparison
SYNX vs IMRN Comparison
Compare SYNX & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYNX
- IMRN
- Stock Information
- Founded
- SYNX 2005
- IMRN 1994
- Country
- SYNX Israel
- IMRN Australia
- Employees
- SYNX N/A
- IMRN N/A
- Industry
- SYNX
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SYNX
- IMRN Health Care
- Exchange
- SYNX Nasdaq
- IMRN Nasdaq
- Market Cap
- SYNX 9.7M
- IMRN 10.1M
- IPO Year
- SYNX 2024
- IMRN N/A
- Fundamental
- Price
- SYNX $1.85
- IMRN $1.72
- Analyst Decision
- SYNX
- IMRN Strong Buy
- Analyst Count
- SYNX 0
- IMRN 1
- Target Price
- SYNX N/A
- IMRN $5.00
- AVG Volume (30 Days)
- SYNX 26.7K
- IMRN 22.7K
- Earning Date
- SYNX 05-21-2025
- IMRN 05-06-2025
- Dividend Yield
- SYNX N/A
- IMRN N/A
- EPS Growth
- SYNX N/A
- IMRN N/A
- EPS
- SYNX N/A
- IMRN N/A
- Revenue
- SYNX $9,893,000.00
- IMRN $4,048,286.00
- Revenue This Year
- SYNX $52.34
- IMRN N/A
- Revenue Next Year
- SYNX N/A
- IMRN N/A
- P/E Ratio
- SYNX N/A
- IMRN N/A
- Revenue Growth
- SYNX 18.05
- IMRN 82.90
- 52 Week Low
- SYNX $1.71
- IMRN $1.60
- 52 Week High
- SYNX $6.49
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- SYNX 30.89
- IMRN 46.67
- Support Level
- SYNX $1.74
- IMRN $1.64
- Resistance Level
- SYNX $1.94
- IMRN $1.91
- Average True Range (ATR)
- SYNX 0.16
- IMRN 0.16
- MACD
- SYNX 0.02
- IMRN 0.00
- Stochastic Oscillator
- SYNX 21.12
- IMRN 31.00
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat-proven. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both in training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, market and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.